Brief: BELLUS Health Reports Q3 Loss Per Share $0.09

BELLUS Health

12/11/2020 12:16

Nov 12 (Reuters) - BELLUS Health Inc  BLU.TO :
    * BELLUS HEALTH REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS
AND
BUSINESS HIGHLIGHTS
    * BELLUS HEALTH INC - FOLLOWING RECENT FDA MEETING, PHASE 2B
SOOTHE TRIAL IN REFRACTORY CHRONIC COUGH PATIENTS REMAINS ON
TRACK TO INITIATE IN Q4 2020
    * BELLUS HEALTH INC - PHASE 2 BLUEPRINT TRIAL IN CHRONIC
PRURITUS
ASSOCIATED WITH ATOPIC DERMATITIS REMAINS ON TRACK TO INITIATE
IN Q4 2020
    * BELLUS HEALTH INC - RECENTLY COMPLETED $40 MILLION
OFFERING OF
SHARES PROVIDES EXTENDED CASH RUNWAY TO END OF 2022
    * BELLUS HEALTH INC - RESULTS FROM BLUEPRINT PHASE 2
CLINICAL
TRIAL OF BLU-5937 IN CHRONIC PRURITUS ASSOCIATED WITH AD
EXPECTED IN 2021
    * BELLUS HEALTH INC - QTRLY LOSS PER SHARE US$0.09

Source text for Eikon:  ID:nBw5cf7NHa 
Further company coverage:  BLU.TO 

 ((Reuters.Briefs@thomsonreuters.com;))